The Inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects

Obesity

Volumn 21, Issue 2, 2013, Pages 361-366

  Dullaart, Robin P F ^a   De Boer, Jan Freark ^a   Annema, Wijtske ^a,b   Tietge, Uwe J F ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIOXIDANTS; APOLIPOPROTEIN A-I; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SERUM AMYLOID A PROTEIN;

EID: 84876231617     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20058     Document Type: Article

References (39)

1. Prospective Studies Collaboration, Lewington S, Whitlock G et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-1839.
2. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
3. Kappelle PJ, Gansevoort RT, Hillege JL, Wolffenbuttel BH, Dullaart RPF; PREVEND study group. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med 2011;269:232-242.
4. Borggreve SE, de Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin invest 2003;33:1051-1069. (Pubitemid 38019139)
5. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-374. (Pubitemid 44394906)
6. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009;58: 2711-2717.
7. Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RPF. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 2010;40:483-489.
8. Dullaart RPF. Increased coronary heart disease risk determined by high high-density lipoprotein cholesterol and C-reactive protein: modulation by variation in the CETP gene. Arterioscler Thromb Vasc Biol 2010;30:1502-1503.
9. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004;37:1986-1994. (Pubitemid 39491318)
10. Chait A, Han CY, Oram JF, Heinecke JW. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46: 389-403. (Pubitemid 43109774)
11. Alwaili K, Bailey D, Awan Z et al. HDLproteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 2011; Epub ahead of print.
12. Davidsson P, Hulthe J, Fagerberg B, Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010;30:156-163.
13. Chetty PS, Mayne L, Lund-Katz S, Stranz D, Englander SW, Phillips MC. Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci USA 2009;106:19005-19010.
14. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986;261:9644-9651. (Pubitemid 17214087)
15. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843. (Pubitemid 30165206)
16. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726-732. (Pubitemid 38222891)
17. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204. (Pubitemid 30459555)
18. Jylhävä J, Haarala A, Eklund C, et al. Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study. J Intern Med 2009;266:286-295.
19. Jacobs M, van Greevenbroek MM, van der Kallen CJ, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009;39:437-444.
20. Kappelle PJWH, Bijzet J, Hazenberg BP, Dullaart RPF. Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res 2011;42:219-225.
21. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004;89:4963-4971. (Pubitemid 39391435)
22. Annema W, Nijstad N, Tölle M, et al. Myeloperoxidase and serum amylod A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not groupIIA secretory phospholipase A2. J Lipid Res 2010;51:743-754.
23. Mulder DJ, de Boer JF, Graaff R, et al. Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis 2011; 218:102-106.
24. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752. (Pubitemid 41532612)
25. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 2011;123:114-119.
26. Nijstad N, de Boer JF, Lagor WR, et al. Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice. Biochim Biophys Acta 2011;1811:294-299.
27. Tietge UJ, Pratico D, Ding T, et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 2005;46:1604-1614. (Pubitemid 41099327)
28. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999;58:96-102. (Pubitemid 29116309)
29. Selvin S. Statistical analysis of epidemiological data. New York: Oxford University press; 1996.
30. Kappelle PJ, de Boer JF, Perton FG, et al. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 2012;42: 487-95.
31. Kontush A, de Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005;182:277-285. (Pubitemid 41267195)
32. Dullaart RPF, Constantinides A, Perton FG, et al. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. J Clin Endocrinol Metab 2011;96:1077-1084.
33. Dullaart RPF, Groen AK, Dallinga-Thie GM, de Vries R, Sluiter WJ, van Tol A. Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low HDL cholesterol. Eur J Endocrinol 2008;158:53-60. (Pubitemid 351211040)
34. Nobécourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010; 30:766-772.
35. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-320. (Pubitemid 30163474)
36. Kotani K, Satoh N, Kato Y, et al. A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome. Atherosclerosis 2009;204:526-31.
37. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-338.
38. Kujiraoka T, Iwasaki T, Ishihara M, et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 2003;44:2006-2014. (Pubitemid 37356674)
39. Constantinides A, van Pelt LJ, van Leeuwen JJ, et al. Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest 2011;41:820-827.